In ALS mouse models SOD1-G93A [301] and TDP-43-A315T [302], administration of a CB2 agonist (AM1241 0.3 or 3 mg/kg/day i.p. [301], or HU308 5 mg/kg/day i.p. [302]) from symptom onset prolonged survival in the AM1241 study and improved motor function and contributed to the preservation of motor neurons in the HU308 study. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.